| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy.
|
Blood
|
2001
|
1.99
|
|
2
|
Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide.
|
Br J Haematol
|
1997
|
1.48
|
|
3
|
Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor)
|
Blood
|
1995
|
1.43
|
|
4
|
Intensive treatment of renal failure in patients with myeloma.
|
Clin Lab Haematol
|
1994
|
1.43
|
|
5
|
Economic evaluation of peripheral blood stem cell transplantation for lymphoma.
|
Lancet
|
1992
|
1.40
|
|
6
|
The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison.
|
Leukemia
|
2012
|
1.39
|
|
7
|
Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres.
|
Br J Haematol
|
2001
|
1.36
|
|
8
|
Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation.
|
Bone Marrow Transplant
|
1998
|
1.30
|
|
9
|
Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles.
|
Leukemia
|
2009
|
1.29
|
|
10
|
Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation.
|
Lancet
|
1993
|
1.24
|
|
11
|
Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia.
|
Blood
|
1999
|
1.18
|
|
12
|
Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.
|
Bone Marrow Transplant
|
2010
|
1.16
|
|
13
|
Microsatellite instability occurs in defined subsets of patients with acute myeloblastic leukaemia.
|
Br J Haematol
|
2001
|
1.10
|
|
14
|
Pregnancy associated aplastic anaemia: a report of five cases and review of current management.
|
Br J Haematol
|
1989
|
1.08
|
|
15
|
Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant.
|
Bone Marrow Transplant
|
2008
|
1.08
|
|
16
|
Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia.
|
Br J Haematol
|
2003
|
1.05
|
|
17
|
Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia.
|
Leukemia
|
2009
|
1.01
|
|
18
|
Effective prevention of acute GVHD following allogeneic BMT with low leukaemic relapse using methotrexate and therapeutically monitored levels of cyclosporin A.
|
Bone Marrow Transplant
|
1992
|
1.01
|
|
19
|
Functional hyposplenism following allogeneic bone marrow transplantation.
|
J Clin Pathol
|
1995
|
0.99
|
|
20
|
DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412.
|
Leukemia
|
2006
|
0.98
|
|
21
|
Abnormal fibrinolytic activity in systemic lupus erythematosus and possible mechanisms.
|
Br J Rheumatol
|
1988
|
0.98
|
|
22
|
The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants.
|
Bone Marrow Transplant
|
2005
|
0.98
|
|
23
|
Bone marrow transplantation: current situation, complications and prevention.
|
J Antimicrob Chemother
|
1995
|
0.97
|
|
24
|
Fusion of NUP214 to ABL1 on amplified episomes in T-ALL--implications for treatment.
|
Leukemia
|
2005
|
0.97
|
|
25
|
Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome.
|
Br J Haematol
|
2004
|
0.94
|
|
26
|
Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation.
|
Bone Marrow Transplant
|
2011
|
0.94
|
|
27
|
Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C.
|
Leukemia
|
1995
|
0.93
|
|
28
|
Allogeneic bone marrow transplantation for systemic AL amyloidosis.
|
Br J Haematol
|
1998
|
0.89
|
|
29
|
Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit.
|
J Clin Oncol
|
1997
|
0.89
|
|
30
|
Accelerated telomere shortening following allogeneic transplantation is independent of the cell source and occurs within the first year post transplant.
|
Bone Marrow Transplant
|
2001
|
0.89
|
|
31
|
Wild-type p53 is required for apoptosis induced by growth factor deprivation in factor-dependent leukaemic cells.
|
Br J Cancer
|
1994
|
0.88
|
|
32
|
Clinical impact of MRSA in a stem cell transplant unit: analysis before, during and after an MRSA outbreak.
|
Bone Marrow Transplant
|
2007
|
0.88
|
|
33
|
Minimal residual disease after bone marrow transplantation for multiple myeloma: evidence for cure in long-term survivors.
|
Bone Marrow Transplant
|
1993
|
0.87
|
|
34
|
The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry.
|
Leukemia
|
2010
|
0.87
|
|
35
|
Interleukin-1beta maintains an apoptosis-resistant phenotype in the blast cells of acute myeloid leukaemia via multiple pathways.
|
Leukemia
|
2004
|
0.86
|
|
36
|
Visceral varicella zoster infection after bone marrow transplantation without skin involvement and the use of PCR for diagnosis.
|
Bone Marrow Transplant
|
1995
|
0.86
|
|
37
|
Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
|
Cytotherapy
|
2001
|
0.86
|
|
38
|
Extramedullary haemopoiesis as a cause of mediastinal lymphadenopathy in chronic myelomonocytic leukaemia.
|
Clin Lab Haematol
|
1990
|
0.86
|
|
39
|
Thrombocytopathy in preleukaemia: association with a defect of thromboxane A2 activity.
|
Br J Haematol
|
1979
|
0.85
|
|
40
|
A novel BCR-ABL fusion gene (e2/1a) in a patient with Philadelphia-positive chronic myelogenous leukaemia and an aggressive clinical course.
|
Br J Haematol
|
1998
|
0.85
|
|
41
|
The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia.
|
Bone Marrow Transplant
|
2000
|
0.84
|
|
42
|
Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant.
|
Bone Marrow Transplant
|
2007
|
0.84
|
|
43
|
Methylation of the hMLH1 promoter and its association with microsatellite instability in acute myeloid leukemia.
|
Leukemia
|
2003
|
0.84
|
|
44
|
Allogeneic peripheral blood stem cell transplantation for haematological malignancies--an analysis of kinetics of engraftment and GVHD risk.
|
Bone Marrow Transplant
|
1997
|
0.84
|
|
45
|
Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG.
|
Leukemia
|
1999
|
0.84
|
|
46
|
Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients.
|
Br J Haematol
|
1994
|
0.84
|
|
47
|
An analysis of the effect of chronic GvHD on relapse and survival following allogeneic PBSC transplantation.
|
Cytotherapy
|
2000
|
0.83
|
|
48
|
Bcl-x(L) is heterogenously expressed by acute myeloblastic leukaemia cells and is associated with autonomous growth in vitro and with P-glycoprotein expression.
|
Leukemia
|
1997
|
0.83
|
|
49
|
Evidence for internal autocrine regulation of growth in acute myeloblastic leukemia cells.
|
Exp Hematol
|
1994
|
0.82
|
|
50
|
Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial.
|
Leukemia
|
2012
|
0.82
|
|
51
|
Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic leukaemia.
|
Br J Haematol
|
2000
|
0.82
|
|
52
|
Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.
|
Br J Haematol
|
2000
|
0.82
|
|
53
|
Down-regulation of bcl-2 in AML blasts by all-trans retinoic acid and its relationship to CD34 antigen expression.
|
Br J Haematol
|
1996
|
0.82
|
|
54
|
Heterogeneous mechanisms of autocrine growth of AML blasts.
|
Br J Haematol
|
1989
|
0.82
|
|
55
|
Flow cytometric chemosensitivity analysis of blasts from patients with acute myeloblastic leukemia and myelodysplastic syndromes: the use of 7AAD with antibodies to CD45 or CD34.
|
Cytometry
|
1999
|
0.81
|
|
56
|
Effect of erythropoietin in patients with myeloma.
|
BMJ
|
1990
|
0.81
|
|
57
|
Nosocomial transmission of Saccharomyces cerevisiae in bone marrow transplant patients.
|
J Hosp Infect
|
2002
|
0.81
|
|
58
|
Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning--evidence for a superior outcome using melphalan combined with total body irradiation.
|
Br J Haematol
|
2005
|
0.81
|
|
59
|
DNA repair mechanisms and acute myeloblastic leukemia.
|
Hematol Oncol
|
2000
|
0.80
|
|
60
|
Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remission.
|
Bone Marrow Transplant
|
2003
|
0.80
|
|
61
|
Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a British National Lymphoma Investigation double-blind, placebo-controlled trial.
|
Br J Haematol
|
1992
|
0.80
|
|
62
|
Successful therapy with ribavirin of late onset respiratory syncytial virus pneumonitis complicating allogeneic bone transplantation.
|
Clin Lab Haematol
|
1992
|
0.79
|
|
63
|
Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a 'graft vs. myelofibrosis' effect.
|
Br J Haematol
|
2000
|
0.79
|
|
64
|
Engraftment and molecular monitoring of CD34+ peripheral-blood stem-cell transplants for follicular lymphoma: a pilot study.
|
J Clin Oncol
|
1997
|
0.79
|
|
65
|
Comparative quantitative expression of bcl-2 by normal and leukaemic myeloid cells.
|
Br J Haematol
|
1995
|
0.79
|
|
66
|
Macrophage-inflammatory protein-1alpha receptor expression on normal and chronic myeloid leukemia CD34+ cells.
|
J Immunol
|
1999
|
0.79
|
|
67
|
Bcl-2 expression in acute myeloblastic leukaemia: relationship with autonomous growth and CD34 antigen expression.
|
Leuk Lymphoma
|
1997
|
0.79
|
|
68
|
High dose melphalan or intermediate dose melphalan can be well tolerated and result in good response rates in selected elderly patients with myeloma.
|
Leuk Res
|
2007
|
0.78
|
|
69
|
Vincristine, adriamycin and high dose steroids in myeloma complicated by renal failure.
|
Br J Cancer
|
1990
|
0.78
|
|
70
|
Cerebral vasculitis associated with hairy cell leukemia.
|
Cancer
|
1987
|
0.78
|
|
71
|
Therapeutic selectivity of and predication of response to 2'-deoxycoformycin in acute leukaemia.
|
Lancet
|
1981
|
0.78
|
|
72
|
The effect of deoxycoformycin and deoxyadenosine on deoxyribonucleotide concentrations in leukaemic cells.
|
Br J Haematol
|
1982
|
0.78
|
|
73
|
Detection of clonal immunoglobulin gene rearrangements in the peripheral blood progenitor cells of patients with multiple myeloma: the potential role of purging with CD34 positive selection.
|
Clin Mol Pathol
|
1996
|
0.78
|
|
74
|
Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: conditioning protocols and donor selection algorithms.
|
Bone Marrow Transplant
|
2009
|
0.78
|
|
75
|
Studies on the biochemical sequelae of therapy in Thy-acute lymphoblastic leukaemia with the adenosine deaminase inhibitor 2' deoxycoformycin.
|
Br J Haematol
|
1981
|
0.77
|
|
76
|
Functional multidrug resistance in acute myeloblastic leukaemia: a standardized flow cytometric assay for intracellular daunorubicin accumulation.
|
Br J Haematol
|
1998
|
0.77
|
|
77
|
Engraftment characteristics of peripheral blood stem cells mobilised with cyclophosphamide and the delayed addition of G-CSF.
|
Bone Marrow Transplant
|
1995
|
0.77
|
|
78
|
Interaction of aluminium and gallium with human lymphocytes: the role of transferrin.
|
Biochim Biophys Acta
|
1991
|
0.77
|
|
79
|
Naso-jejunal feeding in allogeneic bone marrow transplant recipients: results of a pilot study.
|
Bone Marrow Transplant
|
2001
|
0.77
|
|
80
|
Role of autocrine and paracrine production of granulocyte-macrophage colony-stimulating factor and interleukin-1 beta in the autonomous growth of acute myeloblastic leukaemia cells--studies using purified CD34-positive cells.
|
Leukemia
|
1992
|
0.77
|
|
81
|
Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
|
Bone Marrow Transplant
|
1998
|
0.77
|
|
82
|
Comparative study of CD34-positive cells and subpopulations in human umbilical cord blood and bone marrow.
|
Bone Marrow Transplant
|
1993
|
0.77
|
|
83
|
Peripheral blood stem cell transplants.
|
J Clin Pathol
|
1998
|
0.77
|
|
84
|
Platelet adenine nucleotides and arachidonic acid metabolism in the myeloproliferative disorders.
|
Thromb Res
|
1981
|
0.76
|
|
85
|
Thrombocytopathy associated with autoimmune haemolytic anaemia.
|
Br Med J
|
1978
|
0.76
|
|
86
|
Interleukin-1 is one factor which regulates autocrine production of GM-CSF by the blast cells of acute myeloblastic leukaemia.
|
Br J Haematol
|
1990
|
0.76
|
|
87
|
Autologous GVHD following PBSCT, with evidence for a graft-versus-myeloma effect.
|
Bone Marrow Transplant
|
1997
|
0.76
|
|
88
|
Allogeneic bone marrow transplant for multiple myeloma.
|
Blood
|
1997
|
0.76
|
|
89
|
Peripheral blood stem cells for allogeneic transplantation.
|
Bone Marrow Transplant
|
1994
|
0.76
|
|
90
|
IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for lymphoma.
|
Br J Haematol
|
2008
|
0.76
|
|
91
|
In vivo Campath for the prevention of GvHD following allogeneic HSCT: effects of dose, schedule and antibody type.
|
Bone Marrow Transplant
|
2004
|
0.75
|
|
92
|
Acute lymphoblastic leukaemia presenting with raised intracranial pressure.
|
Arch Dis Child
|
1985
|
0.75
|
|
93
|
Sensitivity of S. cerevisiae in haematology patients.
|
J Hosp Infect
|
2001
|
0.75
|
|
94
|
G-CSF dosage and scheduling following autologous PBSC transplantation.
|
Bone Marrow Transplant
|
1998
|
0.75
|
|
95
|
Treatment of acute myeloid leukaemia in a renal allograft recipient: implications of cyclosporin immunosuppressive treatment.
|
J Clin Pathol
|
1991
|
0.75
|
|
96
|
Adjuvant alpha-interferon improves complete remission rates following allogeneic transplantation for multiple myeloma.
|
Bone Marrow Transplant
|
1998
|
0.75
|
|
97
|
Second allogeneic transplant for severe aplastic anaemia following late graft rejection.
|
Br J Haematol
|
1999
|
0.75
|
|
98
|
Dendritic cells cultured from mononuclear cells and CD34 cells in myeloma do not harbour human herpesvirus 8.
|
Br J Haematol
|
1998
|
0.75
|
|
99
|
Peripheral blood stem cells from unrelated donors for allogeneic transplantation.
|
Transplantation
|
1999
|
0.75
|
|
100
|
Comments on: Multidrug resistance-associated protein (MRP) expression is correlated with expression of aberrant p53 protein in colorectal cancer, Fukushima Y, Oshika Y, Tokunaga T, et al., Eur J Cancer 1999, 35, 935-938. Mutant p53 and high expression of MRP are associated in acute myeloblastic leukaemia.
|
Eur J Cancer
|
2000
|
0.75
|
|
101
|
Uptake of high-dose therapy and peripheral blood stem cell transplantation in myeloma patients <65 years--the role of the myeloma multi-disciplinary team.
|
Br J Haematol
|
2005
|
0.75
|
|
102
|
Anticorresponding p15 promoter methylation and microsatellite instability in acute myeloblastic leukemia.
|
Blood
|
2000
|
0.75
|
|
103
|
High-dose chemotherapy and autologous peripheral blood stem cell transplantation in lymphoma without blood product support.
|
Bone Marrow Transplant
|
2000
|
0.75
|
|
104
|
Fas receptor-Fas ligand system is independent of both CD34 status and chemosensitivity in acute myeloid leukemia.
|
Exp Hematol
|
2000
|
0.75
|
|
105
|
Blood stem cell allografting.
|
Curr Opin Hematol
|
1995
|
0.75
|
|
106
|
The role of p53 in malignancy.
|
Cancer Treat Res
|
1996
|
0.75
|
|
107
|
Successful engraftment of a second transplant using non-myeloablative conditioning as treatment for graft failure following unrelated donor BMT.
|
Bone Marrow Transplant
|
2001
|
0.75
|
|
108
|
Pentasomy 8 in acute monoblastic leukemia.
|
Cancer Genet Cytogenet
|
2000
|
0.75
|
|
109
|
Ecthyma gangrenosum.
|
Eur J Haematol
|
2002
|
0.75
|
|
110
|
Rapid onset retinopathy in a diabetic patient following bone marrow transplantation.
|
Bone Marrow Transplant
|
2000
|
0.75
|
|
111
|
Successful mobilisation of blood stem cells following previous autologous bone marrow transplantation.
|
Bone Marrow Transplant
|
1996
|
0.75
|
|
112
|
Reproducible flow cytometric methodology for measuring multidrug resistance in leukaemic blasts.
|
Adv Exp Med Biol
|
1999
|
0.75
|
|
113
|
Low dose erythropoietin is effective in reducing transfusion requirements following allogeneic HSCT.
|
Transfus Med
|
2005
|
0.75
|
|
114
|
Blast maturity and CD34 expression determine the effects of the differentiating agents KH1060 and 9-cis-retinoic acid on the differentiation and clonogenicity of non-M3 acute myeloid leukaemia cells.
|
Leukemia
|
1998
|
0.75
|
|
115
|
A comparison of two different systems for CD34+ selection of autologous or allogeneic PBSC collections.
|
J Hematother
|
1998
|
0.75
|
|
116
|
Use of haemopoietic growth factors: commentary on the ASCO/ECOG guidelines. American Society of Clinical Oncology/Eastern Co-operative Oncology Group.
|
Blood Rev
|
1997
|
0.75
|
|
117
|
The role of cell contact and autostimulatory soluble factors in the proliferation of blast cells in acute myeloblastic leukemia.
|
Leukemia
|
1989
|
0.75
|
|
118
|
Transferrin receptor expression of AML blasts is related to their proliferative potential.
|
Br J Haematol
|
1988
|
0.75
|
|
119
|
Use of standardized flow cytometric determinants of multidrug resistance to analyse response to remission induction chemotherapy in patients with acute myeloblastic leukaemia.
|
Br J Haematol
|
1999
|
0.75
|
|
120
|
Abnormalities of retinoblastoma gene expression in hematological malignancies.
|
Leuk Lymphoma
|
1995
|
0.75
|
|
121
|
Opsoclonus myoclonus following allogeneic haematopoietic stem cell transplantation.
|
Bone Marrow Transplant
|
2005
|
0.75
|
|
122
|
The relative sensitivity of peripheral blood T-lymphocyte colony forming cells and bone marrow CFU-GM to deoxyadenosine and 2'deoxycoformycin.
|
Leuk Res
|
1985
|
0.75
|
|
123
|
Potential use of purine nucleosides and enzyme inhibitors for selective depletion of Thy-lymphoblasts from human bone marrow.
|
Leuk Res
|
1986
|
0.75
|
|
124
|
Comparative serial quantitative measurements of chimaerism following unmanipulated allogeneic transplantation of peripheral blood stem cells and bone marrow.
|
Br J Haematol
|
1999
|
0.75
|
|
125
|
Hypoplastic acute leukemia: cytogenic evidence for differentiation in vivo in response to low-dose ara-C.
|
Br J Haematol
|
1987
|
0.75
|
|
126
|
Low incidence of human herpesvirus 8 in stem cell collections from myeloma patients.
|
Bone Marrow Transplant
|
1999
|
0.75
|
|
127
|
Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the Clinical Trials Committee of the British Society of Blood & Marrow Transplantation (BSBMT).
|
Bone Marrow Transplant
|
2005
|
0.75
|
|
128
|
Novel combination chemotherapy for primary (AL) amyloidosis myeloma: clinical, laboratory and serum amyloid-P protein scan improvement.
|
Br J Haematol
|
2003
|
0.75
|
|
129
|
High-dose melphalan followed by radical radiotherapy for the treatment of massive plasmacytoma of the chest wall.
|
Bone Marrow Transplant
|
2003
|
0.75
|